Effect of vitamin D on regression to normal glucose regulation and individual glycemic measures: A secondary analysis among participants adherent to the trial protocol in the randomized clinical trial vitamin D and type 2 diabetes (D2d) study
Authors' conclusion
In secondary analyses among participants adherent to the trial protocol, vitamin D lowered risk of developing diabetes and increased likelihood of NGR at the end of the study.
Study context
- Population
- D2d study participants adherent to the trial protocolper-protocol
- Participants
- 2,423 participants
- Comparison
- Vitamin D vs placebo
- Primary endpoint
- Time to new-onset normal glucose regulation (NGR): NGR-1 (2-or-3 glycemic criteria in normal range) or NGR-2 (FPG and 2hPG in normal range)
Methodological detailsper-protocol analysis
- Per-protocol analysis
Primary result
As reported in the abstract
Time to new-onset NGR
HR for new-onset NGR-1 (2-or-3 glycemic criteria in normal range)
1.16
95%CI 0.99, 1.36
HR for new-onset NGR-2 (fasting plasma glucose (FPG) and 2hPG in normal range)
1.06
95%CI 0.87, 1.30
Further findings
| Outcome | Vitamin D | Placebo | Rate ratio (CI) | |
|---|---|---|---|---|
| NGR-1 at last study visit | 12.4% | 9.5% | 1.31 (1.02–1.70) | |
| NGR-2 at last study visit | 8.7% | 6.0% | 1.45 (1.05–2.00) | |
| 0.512Rate ratio (log scale) |
Time to new-onset diabetes
- HR for diabetes
- 0.84 (95%CI 0.71, 0.99)
- Per-protocol analyses
Change in FPG, HbA1c and 2hPG · during follow-up
- Mean difference in FPG favored vitamin D
- −0.80 mg/dL (95%CI −1.26, −0.33)
- FPG, HbA1c and 2hPG increased in both groups
Original publication
Effect of vitamin D on regression to normal glucose regulation and individual glycemic measures: A secondary analysis among participants adherent to the trial protocol in the randomized clinical trial vitamin D and type 2 diabetes (D2d) study. Diabetes Res Clin Pract. Published 19 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →